Over the past decade, obesity’s perception and treatment shifted toward personalized, multifactorial approaches. With 42% of American adults battling obesity, the pharmaceutical industry eyes a $100-200 billion market by 2030. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, both GLP-1 agonists, lead the way, but challenges persist. Non-responsive patients and severe side effects highlight the need for precision in obesity medicine. This era emphasizes a tailored strategy to address the complexity of this prevalent health concern.
Related Posts
Antibiotic Resistance: Cause and Mechanism
Scope of antibiotic resistance problem: Antibacterial-resistant strains and species, occasionally referred as “superbugs”, now contribute to the emergence of diseases that were well controlled few decades ago. In a recent report “Antibiotic Resistance Threats in the United States, 2013,” CDC calls this as a critical health threat for the country. According to the report more […]
CMR Revolution: A New Era in Nonischemic Cardiomyopathy Risk Stratification
Nonischemic cardiomyopathy (NICM) is a leading cause of heart failure and sudden cardiac death (SCD). While left ventricular ejection fraction (LVEF) has been the traditional method for risk stratification, it has limitations in identifying both high- and low-risk patients. Cardiac magnetic resonance (CMR) has emerged as a powerful tool for assessing myocardial scar, a key […]
Effective Strategies for Managing Bartholin’s Duct Cysts and Gland Abscesses
Bartholin’s duct cysts and gland abscesses are common problems that can affect women of reproductive age. Cysts are usually asymptomatic, but they can become enlarged or infected and cause significant pain and discomfort. Abscesses are always painful and require medical treatment. There are a number of effective strategies for managing Bartholin’s duct cysts and gland […]